Researchers warned that faster regulatory approvals in Europe will not solve clinical trial failures without more adaptive trial designs. A study published in Clinical Microbiology and Infection argued that operational issues—especially poor enrollment—drive premature termination of trials, with up to one-third ending early. The authors advocated for regulatory support for adaptive protocols that can evolve during an active study, rather than requiring redesigned protocols each time scientific questions shift. They framed adaptation as a way to reduce waste of public resources tied to failed or prematurely stopped trials. The paper cited pandemic-era experience from CoVacc, a pediatric COVID-19 vaccine study, as an example of how static processes can clash with rapidly changing clinical contexts. The work points to a “paradigm shift” where ongoing review replaces fixed upfront rigidity. For biotech, the message is directly operational: trial design strategy and protocol governance may now matter as much as the drug’s target and endpoints in securing development timelines.